Company

Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Sherlock Biosciences

Main focus: Development of novel Cas-enzymes for diagnostics

Company stage: Commercial (diagnostics), pre-clinical (therapeutics)

Diseases: COVID-19 (diagnostics)

Genome editing tool: CRISPR-Cas12a, CRISPR-Cas12b, CRISPR-Cas13.

Funding stage: Private

Location: Cambridge, MA, USA

Website: https://sherlock.bio/

Partners: Tolo Biotech

Sherlock Biosciences is a CRISPR diagnostics company. The company deploys its SHERLOCK™- and INSPECTR™-platforms that are based on novel Cas-enzymes, and so far, it has commercialised a novel CRISPR-based SARS-CoV-2 detection kit. The company is co-founded by Feng Zhang, who also co-founded Arbor Biotechnologies and Beam Therapeutics.

Sherlock Biosciences, Inc.

Your Latest CMN News

SNIPR Biome Receives CARB-X Funding to Test...

SNIPR Biome announced today that it has secured funding from CARB-X to further advance SNIPR001 into clinical trials in haematological cancer...

CMN Weekly (19 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

A Secondary Checkpoint Refines CRISPR Precision

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing.

Cancer's Weak Point Is Its Metabolism, CRISPR...

American researchers have developed a novel CRISPR-based platform to identify and characterise essential nutrient transporters that support cancer...

Next-Generation CRISPR Screening Libraries Without...

Sponsored content

Founded in 2018, Vivlion is a spin-out of Goethe University Frankfurt. Its mission is to provide innovative gene-editing reagents and screening...

CMN Weekly (12 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

Company: Sherlock Biosciences

Search CRISPR Medicine